Expect results without lifestyle changes - While GLP-1 medications reduce appetite, meaningful weight loss typically requires dietary adjustments and increased physical activity
Compounded drugs are produced in pharmacy facilities under FDA facility regulation, but the finished compounded medication itself does not go through the FDA drug approval process
The cardiovascular evidence is the most solid: in the SELECT trial, people with obesity and established heart disease who added semaglutide cut their risk of cardiovascular death, a second stroke, or a second heart attack by about 20%
However, the timeline varies: some people feel better within days, while others notice symptoms persist for up to 68 weeks, particularly if they increase their dose
Other important safety information Wegovy is FDA approved to treat weight loss in adults with a BMI of 30 or greater
Safety of Clostridium butyricum TOA as a novel food pursuant to Regulation (EU) 2015/2283